SEC Form 3 · accession 0000903423-16-001363
ALBIREO PHARMA, INC. · ALBO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Heather Preston
Director
Period of report
Nov 3, 2016
Accepted (ET)
Nov 14, 2016 · 4:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001322505
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| No securities beneficially ownedF1,F2 | holding | — | — | — | 0 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Dr. Heather Preston is a TPG Partner. TPG is affiliated with TPG Biotechnology Partners II, L.P. ("TPG Biotech II"), which holds 568,638 shares of the Common Stock of Albireo Pharma, Inc. (the "Issuer"), and TPG Biotech II Reinvest AIV L.P. ("TPG Biotech II Reinvest"), which holds 208,458 shares of the Common Stock of the Issuer.
- F2Dr. Preston disclaims beneficial ownership of all of the securities that are or may be beneficially owned by TPG Biotech II or TPG Biotech II Reinvest or any of their affiliates. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that Dr. Preston is, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities of the Issuer for purposes of Section 16 of the Exchange Act or otherwise.
Remarks
(3) Michael LaGatta is signing on behalf of Dr. Preston pursuant to the authorization and designation letter dated October 6, 2016, which is filed as an exhibit to this Form 3.